Skip to content
beroni logo newberoni logo new
  • About
    • About Beroni
    • Our History
    • Board of Directors
    • Management Team
    • Vision, Mission and Values
  • R&D
    • R&D
    • PENAO
      • PENAO Introduction
      • About
      • Board & Senior Management
      • Asset Protection
      • Research & Development​
      • Value Proposition
  • Core Businesses
    • Cell Therapies
    • Anti-Cancer Drugs
    • Infectious Diseases
    • Infectious Diseases – COVID-19
    • E-commerce
  • Products
    • By Beroni China
    • By Beroni USA
    • By Beroni Biotech
  • Investors
    • Announcements
    • Financial Information
    • Corporate Governance
    • Stock Information
    • Globenewswire Press Releases
    • Medtech Outlook
    • Research Report
    • COVID-19 Vaccines Overview
    • FAQs
  • News
  • Contact
  • English
    • 简体中文
Menu Close

GLOBENEWSWIRE PRESS RELEASES

2021 Press Releases

2020 Press Releases

2019 Press Releases

Beroni Group is an international biotechnological company listed on the National Stock Exchange (Australia) and traded on the OTC markets in the USA with business presence in Australia, China, Japan and the USA. It currently has four core businesses – research and development of new drugs and clinical trial, immune cell therapy including gene detection and diagnosis, immunotherapy for cancer treatment, diagnosis of infectious diseases and e-commerce based on the Internet sales of pharmaceutical, healthcare and cosmetic products.

About

  • About Beroni
  • Our History
  • Board of Directors
  • Management Team
  • Vision, Mission, and Values

Core Businesses

  • Cell Therapy
  • Anti-Cancer Drugs
  • Infectious Diseases
  • E-Commerce

Products

  • By Beroni China
  • By Beroni Japan
  • By Beroni USA

Copyrights© Beroni Group 2019 | All rights reserved |

website by chase e-Design

Close Menu